ABU DHABI / GULF TIME In a groundbreaking moment for luxury real estate, the German ...
Read More »Lonza to keep investment high amid vaccine demand
Bloomberg Swiss drug-ingredient maker Lonza Group AG said it plans to keep investment at high levels over the coming years to keep up with demand to manufacture products such as Moderna Inc.’s Covid-19 vaccine. Capital expenditure will be 25% of total revenue this year and remain at such elevated levels for the next few years, the company said on Tuesday. ...
Read More »